Humacyte Inc.

bioengineered tissues, decellularization, regenerative medicine

humacyte.com·United States·Public·$50M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-D7IU

Summary · Eternal Search editorial

Humacyte Inc. bioengineered tissues, decellularization, regenerative medicine

Humacyte is pioneering a platform for investigating, developing, and manufacturing bioengineered human tissues and organs designed to be universally implantable, off-the-shelf, and regenerative. Its platform transforms human cells into tissues intended for tissue repair and replacement across injuries, diseases, and chronic conditions. Its pipeline is built around Acellular Tissue Engineered Vessels, Advanced Organ Systems, and Advanced Tissue Constructs, with Symvess approved for vascular trauma repair in the United States.

The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →

Plate C·01 · Scientific profile

All 16 dimensions
on the record.

Composite18

Chain scale100 pts

Dimensions16

Plate C·02 · Where it sits among peers

Score vs. proximity
to longevity goals.

Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.

Reading

Humacyte Inc. — Near-term readout · Bottom quartile. Derived deterministically from 21 extracted project(s). Most-advanced status: approved. Band: near_readout. Modifiers: +5 depth (3 programs at approved);…

Source: Deterministic

At a glance

Webhumacyte.com

HQUnited States

StagePublic

Headcount215

Publications

47 on file

012026Long-term safety and efficacy outcomes of the Acellular Tissue Engineered Vessel (ATEV) in extremity arterial trauma repair.Journal of vascular surgery cases and innovative techniques→022026Reply: Model Choice and Interpretation in Coronary Tissue Engineering: Still More Questions Than Answers.JACC. Basic to translational science→032025Bioengineered Human Arteries for the Repair of Vascular Injuries.JAMA surgery→042025Short-term performance of Symvess (acellular tissue engineered vessel-tyod) compared to external control data for autologous vein in treatment of extremity arterial injury.Trauma surgery & acute care open→052025Evaluating the Safety and Efficacy of Humacyte Acellular Tissue-Engineered Vessel in a Real-World Combat Setting: A Retrospective Observational Multicenter Study.Military medicine→062025Corrections and Clarifications to Address Concerns About Reporting of Studies of Bioengineered Arteries for Repair of Extremity Vascular Injuries.JAMA surgery→072025Budget impact model of acellular tissue engineered vessel for the repair of extremity arterial trauma when autologous vein is not feasible.Journal of medical economics→082025Bioengineered human blood vessels to treat hospital-acquired vascular complications.Journal of vascular surgery cases and innovative techniques→092025Acellular Tissue Engineered Vessels as Coronary Artery Bypass Grafts.JACC. Basic to translational science→102024Engineered vascular grafts lend unique insight to pathophysiology of aortic aneurysms.Cell stem cell→112023Six-year outcomes of a phase II study of human-tissue engineered blood vessels for peripheral arterial bypass.JVS-vascular science→122023Use of bioengineered human acellular vessels to treat traumatic injuries in the Ukraine-Russia conflict.The Lancet regional health. Europe→132023A Multi-omic Analysis of the Human Lung Reveals Distinct Cell Specific Aging and Senescence Molecular Programs.bioRxiv : the preprint server for biology→142023Evaluation of tissue-engineered human acellular vessels as a Blalock-Taussig-Thomas shunt in a juvenile primate model.JTCVS open→152023Biological mechanisms of infection resistance in tissue engineered blood vessels compared to synthetic expanded polytetrafluoroethylene grafts.JVS-vascular science→162023Evaluation of vascular repair by tissue-engineered human acellular vessels or expanded polytetrafluoroethylene grafts in a porcine model of limb ischemia and reperfusion.The journal of trauma and acute care surgery→172023Biological mechanisms of infection resistance in tissue engineered blood vessels compared to synthetic expanded polytetrafluoroethylene grafts—→182023Evaluation of tissue-engineered human acellular vessels as a Blalock-Taussig-Thomas shunt in a juvenile primate model—→192023Evaluation of vascular repair by tissue-engineered human acellular vessels or expanded polytetrafluoroethylene grafts in a porcine model of limb ischemia and reperfusion—→202023Use of bioengineered human acellular vessels to treat traumatic injuries in the Ukraine-Russia conflict—→212023Six-year outcomes of a phase II study of human-tissue engineered blood vessels for peripheral arterial bypass—→222022Bioengineering Human Tissues and the Future of Vascular Replacement.Circulation research→232022The Human Acellular Vessel for Vascular Reconstruction or Bypass—→

242022Preliminary Experience With the Human Acellular Vessel: A Descriptive Case Series Detailing Early Use of a Bioengineered Blood Vessel for Arterial Repair—→

252022Bioengineering Human Tissues and the Future of Vascular Replacement—→262022Five Year Outcomes in Patients with End Stage Renal Disease Who Received a Bioengineered Human Acellular Vessel for Dialysis Access—→272022Five Year Outcomes in Patients with End Stage Renal Disease Who Received a Bioengineered Human Acellular Vessel for Dialysis Access.EJVES vascular forum→282021Development of a Bioartificial Vascular Pancreas—→292020Bioengineered Human Blood Vessels—→302020Patency of ePTFE Arteriovenous Graft Placements in Hemodialysis Patients: Systematic Literature Review and Meta-Analysis.Kidney360→312020Proteomic Analysis of Infants Undergoing Cardiopulmonary Bypass Using Contemporary Ontological Tools.The Journal of surgical research→322020Bioengineered human blood vessels.Science (New York, N.Y.)→332020Challenges and novel therapies for vascular access in haemodialysis.Nature reviews. Nephrology→342020Vascular access-specific health-related quality of life impacts among hemodialysis patients: qualitative development of the hemodialysis access-related quality of life (HARQ) instrument.BMC nephrology→352020Arterial reconstruction with human bioengineered acellular blood vessels in patients with peripheral arterial disease.Journal of vascular surgery→362019Clinical implementation of the Humacyte human acellular vessel: Implications for military and civilian trauma care.The journal of trauma and acute care surgery→372019Costs Attributable to Arteriovenous Fistula and Arteriovenous Graft Placements in Hemodialysis Patients with Medicare coverage.American journal of nephrology→382019Bioengineered human acellular vessels recellularize and evolve into living blood vessels after human implantation.Science translational medicine→392018Susceptibility of ePTFE vascular grafts and bioengineered human acellular vessels to infection.The Journal of surgical research→402018Lateral fluid flow fractionation using dielectrophoresis (LFFF-DEP) for size-independent, label-free isolation of circulating tumor cells.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences→412017Bioengineered hemodialysis access grafts.The journal of vascular access→422017Arteriovenous Fistulae for Haemodialysis: A Systematic Review and Meta-analysis of Efficacy and Safety Outcomes.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery→432016Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials.Lancet (London, England)→442011Readily available tissue-engineered vascular grafts.Science translational medicine→452011Bioengineered vascular grafts: can we make them off-the-shelf?Trends in cardiovascular medicine→462011An early study on the mechanisms that allow tissue-engineered vascular grafts to resist intimal hyperplasia.Journal of cardiovascular translational research→471999Functional Arteries Grown in Vitro—→

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Humacyte Inc.

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

Loading

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.